Paradigm Biopharma Completes Phase 3 Enrollment, Launches Options Listing
Paradigm Biopharmaceuticals reports Phase‑3 enrolment complete for Zilosul® (iPPS) in knee osteoarthritis, boosting trial confidence and setting up Q1 2027 results – plus an upcoming options listing and investor webinar.
2 minutes to read